首页> 外文期刊>Peritoneal dialysis international: Journal of the International Society for Peritoneal Dialysis >Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study.
【24h】

Use of icodextrin during nocturnal automated peritoneal dialysis allows sustained ultrafiltration while reducing the peritoneal glucose load: a randomized crossover study.

机译:夜间自动腹膜透析期间使用艾考糊精可实现持续超滤,同时降低腹膜葡萄糖负荷:一项随机交叉研究。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Optimization of ultrafiltration and preservation of the peritoneal membrane are desirable objectives in peritoneal dialysis (PD) patients. Mixtures of glucose- and non-glucose-based solutions may help to meet both targets simultaneously. AIM: To analyze the effects, in terms of ultrafiltration and peritoneal glucose load, of including icodextrin-based dialysate in the nocturnal schedule of patients undergoing automated PD (APD). METHOD: Following a randomized crossover design, 17 APD patients underwent two 10-day study periods under identical prescription (including amino acid-based solution for the night schedule), except for the substitution of 2 L glucose-based dialysate in the nocturnal mixture (control) by a similar amount of icodextrin-based dialysate (icodextrin phase) in one period. Dependent variables included ultrafiltration, sodium removal, peritoneal glucose load, and residual renal function. We measured serum and urine levels of icodextrin metabolites at the end of each phase. RESULTS: Ultrafiltration was marginally higher during the icodextrin phase (median 815 vs 763 mL/day, p = 0.07), while peritoneal sodium removal was similar in both phases (74 vs 71 mmol/L/day). Peritoneal glucose load (median 67.5 vs 104.0 g/day, p < 0.005) and absorption (14.0 vs 35.6 g/day, p < 0.005) were lower during the icodextrin phase. Diuresis was also modestly lower during the icodextrin phase (500 vs 600 mL/day, p < 0.05). Serum levels of icodextrin metabolites were moderately higher in the icodextrin phase (p < 0.005) in patients both on and off diurnal icodextrin. CONCLUSION: Inclusion of amino acid- and icodextrin-based solutions in the nocturnal schedule of APD patients may allow sustained ultrafiltration and sodium removal while significantly reducing the peritoneal glucose load in these patients.
机译:背景:超滤的优化和腹膜的保存是腹膜透析(PD)患者的理想目标。葡萄糖和非葡萄糖溶液的混合物可能有助于同时达到两个目标。目的:就超滤和腹膜葡萄糖负荷而言,分析在接受自动PD(APD)的患者的夜间计划中加入基于艾考糊精的透析液的影响。方法:按照随机分频设计,除了在夜间混合液中替代2 L葡萄糖基透析液外,17位APD患者在相同的处方下(包括夜间使用基于氨基酸的溶液)经历了两个为期10天的研究期(在一个时期内通过类似量的基于艾考糊精的透析液(艾考糊精相)进行控制)。因变量包括超滤,除钠,腹膜葡萄糖负荷和残余肾功能。我们在每个阶段结束时测量了艾考糊精代谢产物的血清和尿液水平。结果:在艾考糊精阶段,超滤水平略高(中位数815对763 mL /天,p = 0.07),而两个阶段的腹膜钠去除相似(74对71 mmol / L /天)。在艾考糊精阶段,腹膜葡萄糖负荷(中位值67.5对104.0 g /天,p <0.005)和吸收(14.0对35.6 g /天,p <0.005)较低。在艾考糊精阶段,利尿也略有降低(500 vs 600 mL /天,p <0.05)。昼夜使用艾考糊精的患者在艾考糊精阶段的血清艾考糊精代谢产物水平均较高(p <0.005)。结论:在APD患者的夜间计划中加入基于氨基酸和艾考糊精的溶液可能会持续进行超滤和去除钠,同时显着降低这些患者的腹膜葡萄糖负荷。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号